The relationship between levels of plasma-soluble urokinase plasminogen activator receptor (suPAR) and presence of migraine attack and aura

References

• Ertas M, Baykan B, Orhan EK, et al. One-year prevalence and the impact of migraine and tension-type headache in Turkey: a nationwide home-based study in adults. J Headache Pain 2012;13:147–57.
   PubMed Web of Science ®Google Scholar
• Bolay H, Reuter U, Dunn AK, et al. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat Med 2002;8:136–42.
   PubMed Web of Science ®Google Scholar
• Waeber C, Moskowitz MA. Migraine as an inflammatory disorder. Neurology 2005;2464:S9–S15.
   PubMed Web of Science ®Google Scholar
• Olesen J. International Classification of Headache Disorders, Second Edition (ICHD-2): current status and future revisions. Cephalalgia 2006;26:1409–10.
   PubMed Web of Science ®Google Scholar
• Avci AY, Lakadamyali H, Arikan S, et al. High sensitivity C-reactive protein and cerebral white matter hyperintensities on magnetic resonance imaging in migraine patients. J Headache Pain 2015;16:9.
   PubMed Web of Science ®Google Scholar
• Ceylan M, Bayraktutan OF, Becel S, et al. Serum levels of pentraxin-3 and other inflammatory biomarkers in migraine: association with migrainecharacteristics. Cephalalgia 2016;36:518–25.
   PubMed Web of Science ®Google Scholar
• Enocsson H, Wetterö J, Skogh T, Sjöwall C. Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus. Transl Res 2013;162:287–96.
   PubMed Web of Science ®Google Scholar
• Smith HW, Marshall CJ. Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol 2010;11:23–36.
   PubMed Web of Science ®Google Scholar
• Arbel Y, Strauss BH. suPAR: a cardiac biomarker with a future? Can J Cardiol 2015;31:1223–4.
   PubMed Web of Science ®Google Scholar
• Stephens RW, Pedersen AN, Nielsen HJ, et al. ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients. Clin Chem 1997;43:1868–76.
   PubMed Web of Science ®Google Scholar
• Ostrowski SR, Piironen T, Høyer-Hansen G, et al. High plasma levels of intact and cleaved soluble urokinase receptor reflect immune activation and are independent predictors of mortality in HIV-1-infected patients. J Acquir Immune Defic Syndr 2005;39:23–31.
   PubMed Web of Science ®Google Scholar
• Huttunen R, Syrjanen J, Vuento R, et al. Plasma level of soluble urokinase-type plasminogen activator receptor as a predictor of disease severity and case fatality in patients with bacteraemia: a prospective cohort study. J Intern Med 2011;270:32–40.
   PubMed Web of Science ®Google Scholar
• Langkilde A, Hansen TW, Ladelund S, et al. Increased plasma soluble uPAR level is a risk marker of respiratory cancer in initially cancer-free individuals. Cancer Epidemiol Biomarkers Prev 2011;20:609–18.
   PubMed Web of Science ®Google Scholar
• Lee JY, Hwang SJ, Shim JW, et al. Clinical significance of serum procalcitonin in patients with community-acquired lobar pneumonia. Korean J Lab Med 2010;30:406–13.
   PubMedGoogle Scholar
• Pourakbari B, Mamishi S, Zafari J, et al. Evaluation of procalcitonin and neopterin level in serum of patients with acute bacterial infection. Braz J Infect Dis 2010;14:252–5.
   PubMed Web of Science ®Google Scholar
• Soltysiak J, Zachwieja J, Benedyk A, et al. Circulating suPAR as a biomarker of disease severity in children with proteinuric glomerulonephritis. Minerva Pediatr 2016. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Kurtipek GS, Kesli R, Akyurek FT, et al. Plasma-soluble urokinase plasminogen activator receptor (suPAR) levels in Behçet's disease and correlation with disease activity. Int J Rheum Dis 2016. [Epub ahead of print]. doi: 10.1111/1756-185X.12873.
   Web of Science ®Google Scholar
• Kurtipek GS, Kesli R, Akyürek FT, et al. Plasma-soluble urokinase plasminogen activator receptor (suPAR) levels in psoriasis patients and correlation with disease severity. Acta Dermatovenerol Alp Pannonica Adriat 2015;24:73–5.
   PubMedGoogle Scholar
• Cyrille NB, Villablanca PA, Ramakrishna H. Soluble urokinase plasminogen activation receptor – an emerging new biomarker of cardiovascular disease and critical illness. Ann Card Anaesth 2016;19:214–16.
   PubMed Web of Science ®Google Scholar
• Uusitalo-Seppälä R, Huttunen R, Tarkka M, et al. Soluble urokinase-type plasminogen activator receptor in patients with suspected infection in the emergency room: a prospective cohort study. J Intern Med 2012;272:247–56.
   PubMed Web of Science ®Google Scholar
• Koch A, Tacke F. Risk stratification and triage in the emergency department: has this become 'suPAR' easy? J Intern Med 2012;272:243–6.
   PubMed Web of Science ®Google Scholar
• Boc´kowski L, Sobaniec W, Zelazowska-Rutkowska B. Proinflammatory plasma cytokines in children with migraine. Pediatr Neurol 2009;41:17–21.
   PubMed Web of Science ®Google Scholar
• Edsfeldt A, Nitulescu M, Grufman H, et al. Soluble urokinase plasminogen activator receptor is associated with inflammation in the vulnerable human atherosclerotic plaque. Stroke 2012;43:3305–12.
   PubMed Web of Science ®Google Scholar
• Borné Y, Persson M, Melander O, et al. Increased plasma level of soluble urokinase plasminogen activator receptor is associated with incidence of heart failure but not atrial fibrillation. Eur J Heart Fail 2014;16:377–83.
   PubMed Web of Science ®Google Scholar
• Dalkara T, Nozari A, Moskowitz MA. Migraine aura pathophysiology: the role of blood vessels and microembolisation. Lancet Neurol 2010;9:309–17.
   PubMed Web of Science ®Google Scholar
• Murinova N, Krashin DL, Lucas S. Vascular risk in migraineurs: interaction of endothelial and cortical excitability factors. Headache 2014;54:583–90.
   PubMed Web of Science ®Google Scholar
• Turan H, Horasanli B, Ugur M, Arslan H. Procalcitonin levels in migraine patients. Can J Neurol Sci 2011;38:124–8.
   PubMed Web of Science ®Google Scholar
• Fibrinogen Studies Collaboration, Kaptoge S, White IR, Thompson SG, et al. Associations of plasma fibrinogen levels with established cardiovascular disease risk factors, inflammatory markers, and other characteristics: individual participant meta-analysis of 154,211 adults in 31 prospective studies: the fibrinogen studies collaboration. Am J Epidemiol 2007;166:867–79.
   PubMed Web of Science ®Google Scholar
• Nielsen VG, Kulin W, LaWall JS, et al. Chronic migraineurs form carboxyhemefibrinogen and iron-bound fibrinogen. CNS Neurol Disord Drug Targets 2015;14:1079–85.
   PubMed Web of Science ®Google Scholar
• Yucel Y, Tanriverdi H, Arıkanoglu A, et al. Increased fibrinogen, D-dimer and galectin-3 levels in patients with migraine. Neurol Sci 2014;35:545–9.
   PubMed Web of Science ®Google Scholar
• Yilmaz N, Aydin O, Yegin A, et al. Increased levels of total oxidant status and decreased activity of arylesterase in migraineurs. Clin Biochem 2011;44:832–7.
   PubMed Web of Science ®Google Scholar
• Wabnitz A, Bushnell C. Migraine, cardiovascular disease, and stroke during pregnancy: systematic review of the literature. Cephalalgia 2015;35:132–9.
   PubMed Web of Science ®Google Scholar
• Li H, Yu Y. Association between ischemic stroke and migraine in elderly Chinese: a case-control study. BMC Geriatr 2013;13:126.
   PubMed Web of Science ®Google Scholar
• Reichsoellner M, Raggam RB, Wagner J, et al. Clinical evaluation of multiple inflammation biomarkers for diagnosis and prognosis for patients with systemic inflammatory response syndrome. J Clin Microbiol 2014; 52:4063–6.
   PubMed Web of Science ®Google Scholar
• Kurth T, Tzourio C, Bousser MG. Migraine: a matter of the heart? Circulation 2008;118:1405–7.
   PubMed Web of Science ®Google Scholar
• Vanmolkot FH, de Hoon JN. Increased C-reactive protein in young adult patients with migraine. Cephalalgia 2007;27:843–6.
   PubMed Web of Science ®Google Scholar
• Gu¨zel I, Tas demir N, Celik Y. Evaluation of serum transforming growth factor b1 and C-reactive protein levels in migraine patients. Neurol Neurochir Pol 2013;47:357–62.
   PubMed Web of Science ®Google Scholar
• Kurth T, Schürks M, Logroscino G, et al. Migraine, vascular risk, and cardiovascular events in women: prospective cohort study. BMJ 2008;337:a636.
   PubMed Web of Science ®Google Scholar
• Gudmundsson LS, Aspelund T, Scher AI, et al. C-reactive protein in migraine sufferers similar to that of non-migraineurs: the Reykjavik Study. Cephalalgia 2009;29:1301–10.
   PubMed Web of Science ®Google Scholar
• Guldiken B, Guldiken S, Demir M, et al. Insulin resistance and high sensitivity C-reactive protein in migraine. Can J Neurol Sci 2008;35:448–51.
   PubMed Web of Science ®Google Scholar
• Guldiken S, Guldiken B, Demir M, et al. Soluble CD40 ligand and prolactin levels in migraine patients during interictal period. J Headache Pain 2011;12:355–60.
   PubMed Web of Science ®Google Scholar
• Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004;24:9–160.
   Google Scholar
• Van Dongen RM, Zielman R, Noga M, et al. Migraine biomarkers in cerebrospinal fluid: a systematic review and meta-analysis. Cephalalgia 2017;37:49–63.
   PubMed Web of Science ®Google Scholar
• Lippi G, Mattiuzzi C, Cervellin G. C-reactive protein and migraine. Facts or speculations? Clin Chem Lab Med 2014;52:1265–72.
   PubMed Web of Science ®Google Scholar